Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 558 of 6351
-
New immune-boosting combo targets stubborn lymphoma
Disease control Recruiting nowOpen Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination with Rituximab in subjects with Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.
Phase 2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo aims to boost cervical cancer treatment
Disease control Recruiting nowThis study is a clinical study to evaluate the safety and efficacy of Iparomlimab/Tuvonralimab Injection (QL1706, a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies) in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Ca…
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug and high-tech scans aim to calm thyroid eye disease
Disease control Recruiting nowThis is a prospective study designed to evaluate the efficacy and safety of Teprotumumab N01 in patients with Thyroid Eye Disease (TED). Eligible patients will receive Teprotumumab N01 and will be assessed using clinical and imaging parameters before and after treatment, with eac…
Sponsor: Peking University Third Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThe goal of this clinical trial is to learn if anti-CCR9 CAR T cells (which will be made using the patient's own blood cells) are safe and which dose should be used in children and adults with T cell leukaemia and lymphoma. Participants will: * have T cells collected from their…
Phase 1 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New combo therapy aims to boost stroke recovery
Disease control Recruiting nowThis multicenter, prospective, double-blind, placebo-controlled, randomized trial (ANGEL-DRUG2) aims to evaluate the efficacy and safety of intravenous tirofiban following intravenous thrombolysis in patients with acute ischemic stroke who show insufficient neurological improveme…
Phase 4 • Sponsor: Beijing Anzhen Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Organic veggies for pregnant women: a green prescription to cut pesticides?
Prevention Recruiting nowNumerous studies have highlighted the harmful effects of pesticide exposure during the prenatal period. Food is one of the main vectors of exposure to pesticides, particularly glyphosate, which is the most widely used herbicide. Observational studies have highlighted their effect…
Sponsor: University Hospital, Strasbourg, France • Aim: Prevention
Last updated Jun 27, 2026 07:57 UTC
-
AI reads laparoscopy videos to guide ovarian cancer surgery
Diagnosis Not yet recruitingThe standard treatment for advanced ovarian cancer (AOC) is primary cytoreductive surgery (PCS) followed by adjuvant chemotherapy. However, optimal cytoreduction is not always achievable, particularly in cases with high tumor burden or patient frailty. In such scenarios, neoadjuv…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Jun 27, 2026 07:58 UTC
-
Coaching after stroke: a new path back to valued activities?
Symptom relief Recruiting nowThe goal of this clinical trial is to determine whether Occupational Performance Coaching (OPC), a person-centered, strength-based intervention, can improve participation in valued activities among adults who have experienced a stroke and recently completed community- or clinic-b…
Sponsor: Queen's University • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New shot aims to save sight in advanced macular degeneration
Disease control Recruiting nowPhase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
Phase 2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug combo aims to reignite immune attack on tough childhood cancer
Disease control Recruiting nowThe study participant is being asked to take part in this research study because the participant has been diagnosed with neuroblastoma that did not fully respond to previous treatment (refractory), or it has returned after treatment (relapsed). Primary Aims * To evaluate if the…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New cocktail of cancer drugs shows promise for Tough-to-Treat sarcoma
Disease control OngoingThis phase II/III trial compares the effect of vincristine, irinotecan, and regorafenib (VIrR) in combination with vincristine, doxorubicin, cyclophosphamide (VDC), ifosfamide and etoposide (IE) to usual treatment with VDC/IE for the treatment of newly diagnosed Ewing sarcoma or …
Phase 2/3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Chemo-Free hope: new combo before lung surgery shows promise
Disease control Not yet recruitingThe neoadjuvant strategy of immunotherapy combined with chemotherapy has been recommended for resectable or potentially resectable tumors without driver-gene alterations.However, the AE of chemotherapy is more than 40%,which bring fear to the patients,especially for those who can…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Engineered immune cells take on virus-driven cancers in early trial
Disease control Recruiting nowThis is a Phase 1/Phase 2 open-label, single-arm clinical study of GP350 CAR-T for Relapse/Refractory and Epstein-Barr virus infection associated lymphoid neoplasms. Each participant will undergo leukapheresis after enrolment, receive treatment of the conditioning chemotherapy, …
Phase 1/2 • Sponsor: Zhimin Zhai • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Heart valve showdown: open surgery vs. less invasive option – which is better?
Disease control Recruiting nowThe overall hypothesis is that redo aortic valve replacement (rAVR) is superior to valve-invalve transcatheter aortic valve replacement (ViV-TAVR) for the composite endpoint of freedom from all-cause mortality, all-cause stroke, myocardial infarction, and rehospitalization for he…
Sponsor: Heart Center Leipzig - University Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could a chemo fog be the key to fighting ovarian cancer?
Disease control Recruiting nowEvaluation Compared with traditional NACT, whether PIPAC can increase the incidence of CRS3 determines the rationality of choosing PIPAC.
Phase 3 • Sponsor: tongweihua • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug aims to tame rare blood vessel disease
Disease control Recruiting nowThe primary aim is to study the efficacy of treatment with BDB-001 Injection to induce remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combina…
Phase 3 • Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug 608 aims to ease back pain in ankylosing spondylitis
Disease control Recruiting nowThis study will evaluate the efficacy and safety of 608 in patients with AS.
Phase 3 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New heart mapping technique could improve ablation for persistent AF
Disease control OngoingThe purpose of this study is to establish the safety of the pulsed field ablation (PFA) therapy of Pulmonary Veins and Electrographic Flow (EGF) identified extra-PV sources of atrial fibrillation (PVI + EGF ablation of sources) and to demonstrate its non-inferiority in effectiven…
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug combo aims to wipe out rare blood disease
Disease control Recruiting nowThe purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis. The study treatment is divided into cycles (C) and each cycle is 28 days (D). Study treatment is expected to last 6 months.
Phase 2 • Sponsor: Rajshekhar Chakraborty, MD • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New hope for Hard-to-Treat myeloma: QLS32015 enters phase 3 trial
Disease control Recruiting nowThe purpose of this study is to compare the safety and efficacy of QLS32015 with Pd/Sd for the treatment of relapsed or refractory multiple myeloma.
Phase 3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC